Active immunization of hamsters against Clostridium difficile infection using surface-layer protein.
暂无分享,去创建一个
[1] E. Fattal,et al. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. , 2007, Vaccine.
[2] D. Kelleher,et al. Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins , 2005 .
[3] J. Ballard,et al. Clostridium difficile Toxins: Mechanism of Action and Role in Disease , 2005, Clinical Microbiology Reviews.
[4] T. Monath,et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. , 2005, Gastroenterology.
[5] S. Vitovski,et al. Immunoglobulin A1 proteases: a structure-function update. , 2004, Biochemical Society transactions.
[6] Louis Valiquette,et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.
[7] S. Poutanen,et al. Clostridium difficile-associated diarrhea in adults , 2004, Canadian Medical Association Journal.
[8] U. Sleytr,et al. A Novel Approach to Specific Allergy Treatment: The Recombinant Fusion Protein of a Bacterial Cell Surface (S-Layer) Protein and the Major Birch Pollen Allergen Bet v 1 (rSbsC-Bet v 1) Combines Reduced Allergenicity with Immunomodulating Capacity1 , 2004, The Journal of Immunology.
[9] S. Ameer-Beg,et al. Imaging protein-protein interactions in cell motility using fluorescence resonance energy transfer (FRET). , 2004, Biochemical Society transactions.
[10] Y. Matsumoto,et al. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. , 2004, Vaccine.
[11] P. Giannasca,et al. Active and passive immunization against Clostridium difficile diarrhea and colitis. , 2004, Vaccine.
[12] V. Lund,et al. The Aeromonas salmonicida A-layer protein is an important protective antigen in oil-adjuvanted vaccines. , 2003, Fish & shellfish immunology.
[13] B. Lidbury,et al. Antibody-dependent enhancement of infection: bacteria do it too. , 2003, Trends in immunology.
[14] O. Leavy,et al. Cholera Toxin Promotes the Induction of Regulatory T Cells Specific for Bystander Antigens by Modulating Dendritic Cell Activation 1 , 2003, The Journal of Immunology.
[15] F. Audibert. Adjuvants for vaccines, a quest. , 2003, International immunopharmacology.
[16] M. Blaser,et al. Role of S-Layer Protein Antigenic Diversity in the Immune Responses of Sheep Experimentally Challenged with Campylobacter fetus subsp. fetus , 2003, Infection and Immunity.
[17] N. Fairweather,et al. Binding of Clostridium difficile Surface Layer Proteins to Gastrointestinal Tissues , 2002, Infection and Immunity.
[18] M. Murtaugh,et al. Inflammatory cytokines and antigen presenting cell activation. , 2002, Veterinary immunology and immunopathology.
[19] N. Fairweather,et al. Patterns of Sequence Conservation in the S-Layer Proteins and Related Sequences in Clostridium difficile , 2002, Journal of bacteriology.
[20] C. Kelly,et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] S. Davis,et al. Chitosan as a novel nasal delivery system for vaccines. , 2001, Advanced drug delivery reviews.
[22] N. Fairweather,et al. Molecular characterization of the surface layer proteins from Clostridium difficile , 2001, Molecular microbiology.
[23] D. Galloway,et al. Protection against Pseudomonas aeruginosa Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of P. aeruginosa , 2001, Infection and Immunity.
[24] M. Cerquetti,et al. Molecular and Genomic Analysis of Genes Encoding Surface-Anchored Proteins from Clostridium difficile , 2001, Infection and Immunity.
[25] T. Monath,et al. Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults , 2001, Infection and Immunity.
[26] J. Ward,et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. , 2000, Vaccine.
[27] Kearney,et al. Clostridium difficile‐associated diarrhoea in hospitalised patients , 2000, Journal of clinical pharmacy and therapeutics.
[28] R. Page. Vaccination and periodontitis: myth or reality. , 2000, Journal of the International Academy of Periodontology.
[29] D. Kelleher,et al. The Thioredoxin System of Helicobacter pylori* , 2000, The Journal of Biological Chemistry.
[30] S. Romero-Steiner,et al. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. , 1999, The Journal of infectious diseases.
[31] I. Poxton,et al. Variation in the Cell Surface Proteins of Clostridium difficile , 1999 .
[32] J. Brazier,et al. PCR Targeted to the 16S-23S rRNA Gene Intergenic Spacer Region ofClostridium difficile and Construction of a Library Consisting of 116 Different PCR Ribotypes , 1999, Journal of Clinical Microbiology.
[33] T. Monath,et al. Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficileDisease in Hamsters , 1999, Infection and Immunity.
[34] Gupta,et al. Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.
[35] J. Brazier. The epidemiology and typing of Clostridium difficile. , 1998, The Journal of antimicrobial chemotherapy.
[36] U. Sleytr,et al. Toward selective elicitation of TH1-controlled vaccination responses: vaccine applications of bacterial surface layer proteins. , 1996, Journal of biotechnology.
[37] T. Monath,et al. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters , 1995, Infection and immunity.
[38] A. Pantosti,et al. Purification and characterization of an immunodominant 36 kDa antigen present on the cell surface of Clostridium difficile. , 1992, Microbial pathogenesis.
[39] L. Trudel,et al. Comparison of immune response potentiation and in vivo inflammatory effects of Freund's and RIBI adjuvants in mice. , 1992, Laboratory animal science.
[40] M. Delmée,et al. Characterization of flagella of Clostridium difficile and their role in serogrouping reactions , 1990, Journal of clinical microbiology.
[41] G. Welling,et al. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. , 1989, Journal of immunological methods.
[42] A. Pantosti,et al. Immunoblot analysis of serum immunoglobulin G response to surface proteins of Clostridium difficile in patients with antibiotic-associated diarrhea , 1989, Journal of clinical microbiology.
[43] J. Kenney,et al. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. , 1989, Journal of immunological methods.
[44] W. Stamm,et al. Nosocomial acquisition of Clostridium difficile infection. , 1989, The New England journal of medicine.
[45] A. Price,et al. Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis. , 1987, Journal of medical microbiology.
[46] K. Saum,et al. Effects of Clostridium difficile toxins given intragastrically to animals , 1985, Infection and immunity.
[47] J. Bartlett,et al. Clostridium difficile in gnotobiotic mice , 1980, Infection and immunity.
[48] A. Ryan,et al. Sequence and phylogenetic analysis of the gene for surface layer protein, slpA, from 14 PCR ribotypes of Clostridium difficile. , 2006, Journal of medical microbiology.
[49] H. Michie. The value of animal models in the development of new drugs for the treatment of the sepsis syndrome. , 1998, The Journal of antimicrobial chemotherapy.
[50] V. Jennings. Review of Selected Adjuvants Used in Antibody Production. , 1995, ILAR journal.
[51] S. Lofthouse,et al. Comparison of conventional adjuvants and 'adjuvant-free' monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin. , 1993, Vaccine.